Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY)

CUSIP: 75943R102

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
+35,484,908
Put/Call ratio
49%
SEC-reported price per share
$7.08
Number of holders
193
Value change
+$253,277,512
Number of buys
114
Open additional details 1 more signal available
Number of sells
70
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
218,181,818

Security key

75943R102

Report period

Q3 2024

Institutions

193

Top holders

10

Ownership snapshot

Top reported holders of RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
SB INVESTMENT ADVISERS (U...
Disclosed value leader
SB INVESTMENT ADVISERS (U...
Comparable rows
0/15
Latest evidence
30 Jun 2024
13F Highest disclosed value: $181,940,359 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

SB INVESTMENT ADVISERS (UK) LTD has the largest disclosed position value at $181.94M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SB INVESTMENT ADVISERS (UK) LTD's linked filing trail.
Disclosed position value Top 5
SB INVESTMENT ADVISERS (UK) LTD $181.94M
VANGUARD GROUP INC $76.32M
BlackRock Finance, Inc. $68.74M
Casdin Capital, LLC $55.08M
Bellevue Group AG $41.58M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
SB INVESTMENT ADVISERS (UK) LTD
13F
Company
13F
—
denominator unverified
$181,940,359
27,904,963 shares
— 30 Jun 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$76,315,726
11,704,866 shares
— 30 Jun 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$68,738,188
10,542,667 shares
— 30 Jun 2024
Casdin Capital, LLC
13F
Company
13F
—
denominator unverified
$55,084,702
8,448,574 shares
— 30 Jun 2024
Bellevue Group AG
13F
Company
13F
—
denominator unverified
$41,578,790
6,377,115 shares
— 30 Jun 2024
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
13F
—
denominator unverified
$32,855,000
5,039,015 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
193
Shares
163,415,012
Rows available
193
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
171
Q3 2024 holders
193
Holder diff
22
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .